From Startup Arbutus Bio
WARMINSTER, Pa., Oct. 31, 2018 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its third quarter financial results, conference call and webcast for Wednesday, November 7, 2018. The schedule for the press release and conference call/webcast are as follows:
Q3 2018 Press Release:
November 7, 2018 at 4:00 p.m. ET
Q3 2018 Conference Call:
November 7, 2018 at 4:30 p.m. ET
Domestic Dial-In Number:
International Dial-In Number:
Conference ID Number:
A live webcast of the conference call can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-855-859-2056 or 1-404-537-3406, and reference conference ID 2628189.
Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
InvestorsMark MurrayPresident and CEOPhone: 604-419-3200Email: firstname.lastname@example.org
MediaPam MurphyInvestor Relations ConsultantPhone: 604-419-3200Email: email@example.com
Source: Arbutus Biopharma Corporation
Please visit their site for more information: Arbutus Bio.com
All,Biotechnology,Healthcare News,Startup News